$ACAD
ACADIA PHARMACEUTICALS INC Stock $acad

$acad Overview Financials Valuation SEC Filings Company Website

2014 Q4 Form 10-Q Financial Statement

#000119312514406106 Filed on November 10, 2014

Income Statement

Concept	2014 Q4	2014 Q3	2013 Q3
Revenue	$47.00K	$15.00K	$240.0K
YoY Change	27.03%	-93.75%	-93.1%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$10.40M	$8.100M	$3.800M
YoY Change	141.86%	113.16%	153.33%
% of Gross Profit
Research & Development	$18.20M	$16.95M	$7.254M
YoY Change	130.38%	133.69%	64.86%
% of Gross Profit
Depreciation & Amortization	$60.00K	$60.00K	$40.00K
YoY Change	50.0%	50.0%	33.33%
% of Gross Profit
Operating Expenses	$28.60M	$25.01M	$11.05M
YoY Change	134.43%	126.31%	87.78%
Operating Profit		-$24.99M	-$10.81M
YoY Change		131.19%	349.15%
Interest Expense	$200.0K	$208.0K	$116.0K
YoY Change	100.0%	79.31%	2220.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$28.40M	-$24.80M	-$10.70M
YoY Change	136.67%	131.78%	345.83%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$28.37M	-$24.79M	-$10.70M
YoY Change	135.42%	131.75%	345.25%
Net Earnings / Revenue	-60353.19%	-165240.0%	-4456.25%
Basic Earnings Per Share
Diluted Earnings Per Share	-$291.6K	-$249.2K	-$119.6K
COMMON SHARES
Basic Shares Outstanding	99.77M shares	99.44M shares	88.78M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q4	2014 Q3	2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$322.5M	$337.8M	$196.2M
YoY Change	73.58%	72.19%	749.26%
Cash & Equivalents	$61.85M	$36.37M	$11.80M
Short-Term Investments	$260.6M	$301.4M	$184.4M
Other Short-Term Assets	$1.200M	$2.100M	$2.500M
YoY Change	-33.33%	-16.0%	316.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$324.6M	$341.1M	$198.7M
YoY Change	72.34%	71.67%	738.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$553.0K	$520.0K	$490.0K
YoY Change	-4.49%	6.12%	677.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$287.0K	$178.0K	$120.0K
YoY Change	60.34%	48.33%	5900.0%
Total Long-Term Assets	$840.0K	$698.0K	$610.0K
YoY Change	10.82%	14.43%	838.46%
TOTAL ASSETS
Total Short-Term Assets	$324.6M	$341.1M	$198.7M
Total Long-Term Assets	$840.0K	$698.0K	$610.0K
Total Assets	$325.5M	$341.8M	$199.3M
YoY Change	72.09%	71.49%	739.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.016M	$1.110M	$1.120M
YoY Change	441.94%	-0.89%	-0.97%
Accrued Expenses	$13.82M	$10.13M	$6.670M
YoY Change	110.9%	51.84%	42.34%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$15.83M	$11.25M	$7.870M
YoY Change	126.88%	42.99%	29.31%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$100.0K	$0.00	$10.70M
YoY Change		-100.0%
Total Long-Term Liabilities	$135.0K	$21.00K	$2.000K
YoY Change	1587.5%	950.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.83M	$11.25M	$7.870M
Total Long-Term Liabilities	$135.0K	$21.00K	$2.000K
Total Liabilities	$15.97M	$11.27M	$7.872M
YoY Change	128.55%	43.22%	29.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$498.1M	-$469.8M	-$393.6M
YoY Change	22.8%	19.35%	9.06%
Common Stock	$10.00K	$10.00K	$9.000K
YoY Change	11.11%	11.11%	50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$309.5M	$330.5M	$180.8M
YoY Change
Total Liabilities & Shareholders Equity	$325.5M	$341.8M	$199.3M
YoY Change	72.09%	71.49%	739.09%

Cashflow Statement

Concept	2014 Q4	2014 Q3	2013 Q3
OPERATING ACTIVITIES
Net Income	-$28.37M	-$24.79M	-$10.70M
YoY Change	135.42%	131.75%	345.25%
Depreciation, Depletion And Amortization	$60.00K	$60.00K	$40.00K
YoY Change	50.0%	50.0%	33.33%
Cash From Operating Activities	-$17.80M	-$17.48M	-$9.470M
YoY Change	73.32%	84.58%	78.34%
INVESTING ACTIVITIES
Capital Expenditures	-$90.00K	-$80.00K	-$430.0K
YoY Change	-30.77%	-81.4%
Acquisitions
YoY Change
Other Investing Activities	$40.57M	$38.96M	-$3.520M
YoY Change	319.54%	-1206.82%	28.47%
Cash From Investing Activities	$40.48M	$38.87M	-$3.950M
YoY Change	323.87%	-1084.05%	44.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.810M	1.280M	970.0K
YoY Change	346.03%	31.96%	-85.86%
NET CHANGE
Cash From Operating Activities	-17.80M	-17.48M	-9.470M
Cash From Investing Activities	40.48M	38.87M	-3.950M
Cash From Financing Activities	2.810M	1.280M	970.0K
Net Change In Cash	25.49M	22.67M	-12.45M
YoY Change	-28422.22%	-282.09%	946.22%
FREE CASH FLOW
Cash From Operating Activities	-$17.80M	-$17.48M	-$9.470M
Capital Expenditures	-$90.00K	-$80.00K	-$430.0K
Free Cash Flow	-$17.71M	-$17.40M	-$9.040M
YoY Change	74.65%	92.48%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	99770300	shares
CY2014Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-469777000
CY2014Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	15000
CY2014Q3	us-gaap	Preferred Stock Value PreferredStockValue
CY2014Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10128000
CY2014Q3	us-gaap	Liabilities Liabilities	11274000
CY2014Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	21000
CY2014Q3	us-gaap	Common Stock Value CommonStockValue	10000
CY2014Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	341763000
CY2014Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	178000
CY2014Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	301430000
CY2014Q3	us-gaap	Interest Receivable Current InterestReceivableCurrent	1139000
CY2014Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	520000
CY2014Q3	us-gaap	Assets Assets	341763000
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11803000
CY2014Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	99701621	shares
CY2014Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2014Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2014Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	99701621	shares
CY2014Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q3	us-gaap	Liabilities Current LiabilitiesCurrent	11253000
CY2014Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	77000
CY2014Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2466000
CY2014Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	168000
CY2014Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	800179000
CY2014Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1110000
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	330489000
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36369000
CY2014Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	301358000
CY2014Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	43600000
CY2014Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	301430000
CY2014Q3	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	337365000
CY2014Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2127000
CY2014Q3	us-gaap	Assets Current AssetsCurrent	341065000
CY2014Q3	acad	Accrued Consulting And Other Professional Fees AccruedConsultingAndOtherProfessionalFees	1160000
CY2014Q3	acad	Accrued Clinical Development Services AccruedClinicalDevelopmentServices	6334000
CY2014Q3	acad	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	110000
CY2014Q3	acad	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	38000
CY2014Q3	acad	Potential Future Regulatory Milestone Payment PotentialFutureRegulatoryMilestonePayment	10500000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57899000
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	91102618	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	91102618	shares
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6979000
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	48000
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1865000
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	172000
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	587742000
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	372000
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	182131000
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-405668000
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	55000
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6552000
CY2013Q4	us-gaap	Liabilities Liabilities	6987000
CY2013Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	8000
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	9000
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	189118000
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	179000
CY2013Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	174083000
CY2013Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	750000
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	579000
CY2013Q4	us-gaap	Assets Assets	189118000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11707000
CY2013Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	174038000
CY2013Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	174083000
CY2013Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	185831000
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1820000
CY2013Q4	us-gaap	Assets Current AssetsCurrent	188360000
CY2013Q4	acad	Accrued Consulting And Other Professional Fees AccruedConsultingAndOtherProfessionalFees	308000
CY2013Q4	acad	Accrued Clinical Development Services AccruedClinicalDevelopmentServices	4207000
CY2013Q4	acad	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	59000
CY2013Q4	acad	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	14000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-21504000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	83946000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10725000	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.31
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	490000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	80000
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	120000
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	186756000
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	234000
	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	716000
	us-gaap	Revenues Revenues	1108000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1198000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25819000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-26133000
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	10000
	us-gaap	Net Income Loss NetIncomeLoss	-25899000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-938000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	111053000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8444000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-46096000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-135645000
	us-gaap	Operating Expenses OperatingExpenses	27241000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-354000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2531000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-255000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	111053000
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	12000
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2000
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	51589000
	us-gaap	Depreciation Depreciation	40000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3537000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18797000
	dei	Trading Symbol TradingSymbol	ACAD
	dei	Entity Registrant Name EntityRegistrantName	ACADIA PHARMACEUTICALS INC
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2014-09-30
	dei	Entity Central Index Key EntityCentralIndexKey	0001070494
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-48633000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	97210000	shares
	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>10. Recent Accounting Pronouncements</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> In May 2014, the Financial Accounting Standards Board (“FASB”) issued authoritative accounting guidance related to revenue from contracts with customers<i>.</i> This guidance is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This guidance is effective for annual reporting periods beginning after December 15, 2016 and early adoption is not permitted. The Company will adopt this guidance on January 1, 2017. Companies may use either a full retrospective or a modified retrospective approach to adopt this guidance. The Company is evaluating which transition approach to use and its impact, if any, on its consolidated financial statements and related disclosures.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> In August 2014, the FASB issued authoritative accounting guidance related to an entity’s ability to continue as a going concern. This guidance will explicitly require management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. The new standard is effective for annual reporting periods ending after December 15, 2016 and early adoption is permitted. The Company intends to adopt this guidance at the beginning of its first quarter of fiscal year 2016 and does not expect it to have a material impact on its consolidated financial statements and related disclosures.</p> </div>
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9699000	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.66
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y10M24D
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	86000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	29000
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1000
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	307211000
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	567000
	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	389000
	us-gaap	Revenues Revenues	72000
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	11051000
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7254000
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	99497000	shares
CY2014Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9753000	shares
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	307000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-64080000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-64676000
	us-gaap	Net Income Loss NetIncomeLoss	-64109000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-345000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	201044000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22328000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	24662000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-127749000
	us-gaap	Operating Expenses OperatingExpenses	64748000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-40000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3576000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	738000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	201044000
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	13000
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	179548000
	us-gaap	Depreciation Depreciation	145000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11394000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	42420000
	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0
CY2014Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	7360000	shares
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	196800000
CY2013	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	89504000	shares
CY2013Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10523000	shares
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
CY2013Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	110000
CY2013Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	116000
CY2013Q3	us-gaap	Revenues Revenues	240000
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10585000
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-10811000
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-10695000
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3797000
CY2014Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-17000
CY2014Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	208000
CY2014Q3	us-gaap	Revenues Revenues	15000
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24803000
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-24994000
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-24786000
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8057000
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	25009000
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16952000

Files In Submission

Name	View Source	Status
0001193125-14-406106-index-headers.html	Edgar Link	pending
0001193125-14-406106-index.html	Edgar Link	pending
0001193125-14-406106.txt	Edgar Link	pending
0001193125-14-406106-xbrl.zip	Edgar Link	pending
acad-20140930.xml	Edgar Link	completed
acad-20140930.xsd	Edgar Link	pending
acad-20140930_cal.xml	Edgar Link	unprocessable
acad-20140930_def.xml	Edgar Link	unprocessable
acad-20140930_lab.xml	Edgar Link	unprocessable
acad-20140930_pre.xml	Edgar Link	unprocessable
d782118d10q.htm	Edgar Link	pending
d782118dex311.htm	Edgar Link	pending
d782118dex312.htm	Edgar Link	pending
d782118dex321.htm	Edgar Link	pending
d782118dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ACAD
ACADIA PHARMACEUTICALS INC Stock $acad

2014 Q4 Form 10-Q Financial Statement

#000119312514406106 Filed on November 10, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACAD ACADIA PHARMACEUTICALS INC Stock $acad

2014 Q4 Form 10-Q Financial Statement

#000119312514406106 Filed on November 10, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACAD
ACADIA PHARMACEUTICALS INC Stock $acad